查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046944

抗精神病藥物市場－全球產業規模、佔有率、趨勢、機會、預測：按應用、藥物分類、地區和競爭格局分類，2021-2031年

Antipsychotic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Drug Classification (First Generation, Second Generation ), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球抗精神病藥物市場預計將從 2025 年的 157.8 億美元成長到 2031 年的 263.3 億美元，複合年成長率高達 8.91%。

這些關鍵的精神科藥物主要用於治療精神疾病，包括思覺失調症、幻覺和思維障礙等症狀，這些症狀常見於精神分裂症、躁鬱症和重度憂鬱症疾病。市場成長的根本驅動力是全球精神疾病盛行率的上升、診斷能力的提高以及政府為消除精神疾病治療污名化所做的努力。這些因素共同確保了對有效治療性介入的持續需求。世界衛生組織（WHO）預測，到2025年，全球將有超過10億人患有精神疾病，需要持續的長期藥物治療。然而，市場成長面臨的主要障礙是抗精神病藥物普遍存在的嚴重副作用（例如METABOLIC INC.症候群、體重增加和遲發性運動障礙）。這些併發症通常會導致患者依從性降低和治療中斷率升高，從而阻礙現有治療方法充分發揮其商業性潛力，並阻礙穩定的產生收入。

市場概覽
預測期 2027-2031
市場規模：2025年 157.8億美元
市場規模：2031年 263.3億美元
複合年成長率：2026-2031年 8.91%
成長最快的細分市場 思覺失調症
最大的市場 北美洲

抗精神病藥物治療中嚴重副作用的高發生率對全球抗精神病藥物市場的擴張構成重大障礙。METABOLIC INC.症候群、體重增加和遲發性運動障礙等副作用顯著降低了患者對這些藥物的耐受性，迫使許多患者提早停止治療。當患者除了精神疾病外，還出現嚴重損害身體機能的併發症時，他們持續長期藥物治療的動力會急劇下降。治療中斷直接損害了製藥公司賴以生存的持續收入來源，因為實現商業性潛力很大程度上依賴於患者終生持續不間斷的用藥。

市場促進因素

思覺失調症和雙極性情感障礙在全球持續高發，是推動抗精神病藥物市場發展的主要因素。這些慢性且嚴重損害身體機能的疾病需要終身服藥，確保了對抗精神病藥物的穩定需求。診斷標準的不斷改進以及新興經濟體醫療保健體系的擴張，使得需要治療的患者群體不斷增加，直接導致處方量的成長。根據世界衛生組織（世衛組織）2025年10月發布的關於思覺失調症的情況說明書，全球約有2,300萬人將受到影響，凸顯了對更容易取得的治療方案的迫切需求。大塚控股製藥部門2024會計年度的銷售額成長17.1%，也印證了這一點，這主要得益於其精神科藥物產品組合在全球範圍內的持續需求。

同時，長效注射劑（LAI）的普及應用正在加速，有效應對患者依從性低這一普遍挑戰，從而改變了市場格局。 LAI 將給藥頻率從每日口服降低至每月或每兩個月注射一次，顯著改善了治療效果，降低了復發率，並促使臨床醫生優先選擇此類製劑​​而非傳統治療方法。這種臨床轉變降低了治療中斷率，並提高了患者依從性，從而為製藥企業確保了穩定的收入來源。例如，2025 年 2 月，Alcarmes 公司報告稱，其自主研發的 LAI 產品 Aristada 第四季銷售額達到 9,660 萬美元，年成長 16%，充分展現了這種先進給藥機制的巨大商業性潛力。

市場挑戰

抗精神病藥物治療中嚴重副作用的高發生率是全球抗精神病藥物市場成長的主要障礙。METABOLIC INC.症候群、體重增加和遲發性運動障礙等副作用顯著降低了患者對這些藥物的耐受性，常常迫使患者提早停止治療。當患者除了精神疾病外還有其他身體併發症時，他們堅持長期藥物治療的動機會急劇下降。這直接影響了製藥公司賴以生存的持續收入來源，因為商業性成功取決於患者終生持續不間斷用藥。

低藥物依從率帶來的經濟影響巨大，直接阻礙了市場價值。高流失率導致整體藥物消費量下降，儘管全球精神疾病盛行率不斷上升，但銷售成長卻依然緩慢。根據美國國家社區藥劑師協會2025年的數據，高達50%的慢性病患者未能按處方服藥。這種極低的依從率（主要由於耐受性問題）限制了市場充分利用可診斷患者群體的能力，有效地限制了產生收入，並阻礙了整個產業的發展。

市場趨勢

利用非多巴胺能機制的新型抗精神病藥物的出現，標誌著市場格局的重大變革，直接滿足了人們對耐受性更好、療效更佳的治療方法的迫切需求。與主要阻斷多巴胺D2受體、可能導致代謝症候群和運動障礙等副作用的傳統藥物不同，這類創新藥物針對其他系統，例如毒蕈鹼型乙醯膽鹼受體，從而調節精神病症狀。這種模式轉移吸引了眾多製藥公司的巨額投資，這些公司希望從因副作用而停止標準療法的患者群體中搶佔市場佔有率。一個典型的例子是，百時美施貴寶公司於2024年3月以140億美元的股權價值收購了Karna Therapeutics公司，這清楚地表明了製藥業對這些First-in-Class的非多巴胺治療方法的巨額投資。

同時，第三代非典型抗精神病藥物作重度憂鬱症（MDD）輔助治療適應症的擴大，也拓寬了商業性前景。由於單一抗憂鬱症治療複雜病例往往難以達到緩解，臨床醫生擴大將這些藥物作為附加治療方案，從而使更多患者群體受益，而這僅針對思覺失調症時則難以實現。這種適應症的策略性擴展，使製藥公司能夠最大限度地提高其資產的生命週期價值，並維持成長，即便在其他產品組合面臨日益成長的專利壓力的情況下也是如此。例如，2024年4月，艾伯維公司報告稱，其旗艦精神科藥物Vraylar的全球淨銷售額成長了23.6%，達到6.94億美元。這一成長主要歸功於該藥物在情緒障礙治療中的應用日益廣泛，包括作為MDD的聯合治療。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球抗精神病藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依應用領域（思覺失調症、躁鬱症、單相情感障礙、失智症、其他）
    • 藥物分類（第一代（典型），第二代（非典型））
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美抗精神病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲抗精神病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區抗精神病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲抗精神病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲抗精神病藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球抗精神病藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Eli Lily and Company
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co, Ltd.
  • Pfizer Inc.
  • AbbVie Inc.
  • Dr. Reddy's Laboratories Limited
  • Otsuka Holdings Co., Ltd.
  • Teva Pharmaceutical Industries Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16327

The Global Antipsychotic Drugs Market is projected to expand significantly, growing from USD 15.78 Billion in 2025 to USD 26.33 Billion by 2031, at a robust Compound Annual Growth Rate (CAGR) of 8.91%. These essential psychiatric medications are primarily used to manage psychosis, including symptoms like delusions, hallucinations, and disorganized thought processes, commonly associated with conditions such as schizophrenia, bipolar disorder, and severe depression. This market's growth is fundamentally driven by the increasing worldwide prevalence of mental health conditions, enhanced diagnostic capabilities, and governmental efforts to reduce the stigma surrounding psychiatric care. These combined factors ensure a continuous demand for effective therapeutic interventions, underscored by the World Health Organization's projection that over 1 billion people globally will be living with a mental disorder by 2025, necessitating consistent long-term pharmacological management. However, a significant obstacle hindering market growth is the widespread occurrence of severe adverse effects linked to antipsychotic drugs, which include metabolic syndrome, weight gain, and tardive dyskinesia. These complications frequently lead to poor patient adherence and high rates of treatment discontinuation, thereby limiting the full commercial potential of current treatment regimens and creating barriers to stable revenue generation.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 15.78 Billion
Market Size 2031USD 26.33 Billion
CAGR 2026-20318.91%
Fastest Growing SegmentSchizophrenia
Largest MarketNorth America

The prevalence of severe adverse effects associated with antipsychotic pharmacotherapy constitutes a critical barrier to the expansion of the Global Antipsychotic Drugs Market. Side effects such as metabolic syndrome, weight gain, and tardive dyskinesia significantly diminish the tolerability of these medications, forcing many patients to discontinue treatment prematurely. When patients experience debilitating physical complications alongside their psychiatric condition, their willingness to sustain long-term pharmacological regimens declines sharply. This interruption in therapy directly undermines the recurring revenue streams that pharmaceutical manufacturers rely upon, as the realization of commercial potential depends heavily on consistent, uninterrupted usage over a patient's lifetime.

Market Driver

The escalating global prevalence of schizophrenia and bipolar disorders serves as the primary catalyst propelling the antipsychotic drugs market. These chronic and debilitating conditions necessitate lifelong pharmacological management, thereby ensuring a consistent demand for antipsychotic therapeutics. As diagnostic criteria continue to improve and healthcare systems in emerging economies expand, the identified patient population requiring treatment steadily widens, directly translating into increased prescription volumes. According to the World Health Organization's 'Schizophrenia' fact sheet in October 2025, approximately 23 million people worldwide were affected by this disorder, highlighting the critical need for accessible therapeutic options and underpinning the sector's financial resilience, as evidenced by Otsuka Holdings' pharmaceutical segment revenue increasing by 17.1% in fiscal year 2024, largely driven by sustained global demand for its psychiatric medication portfolio.

Simultaneously, the accelerated adoption of Long-Acting Injectable (LAI) formulations is transforming the market landscape by effectively addressing the pervasive issue of patient non-adherence. By reducing the dosing frequency from daily oral intake to monthly or bi-monthly injections, LAIs significantly improve therapeutic outcomes and reduce relapse rates, encouraging clinicians to prioritize these formulations over traditional treatments. This clinical shift lowers discontinuation rates and fosters higher patient compliance, thereby ensuring consistent revenue streams for pharmaceutical manufacturers. Alkermes plc, for instance, reported in February 2025 that revenues for its proprietary LAI product ARISTADA grew 16% year-over-year to $96.6 million in the fourth quarter, illustrating the substantial commercial viability of this advanced delivery mechanism.

Market Challenge

The prevalence of severe adverse effects linked to antipsychotic pharmacotherapy presents a significant obstacle to the growth of the Global Antipsychotic Drugs Market. Side effects such as metabolic syndrome, weight gain, and tardive dyskinesia severely reduce the tolerability of these medications, frequently compelling patients to discontinue treatment prematurely. When individuals face debilitating physical complications in addition to their psychiatric condition, their motivation to maintain long-term pharmacological regimens sharply diminishes, directly disrupting the recurring revenue streams on which pharmaceutical manufacturers depend, as commercial success hinges on consistent, uninterrupted usage throughout a patient's life.

The economic repercussions of this non-adherence are substantial and directly impede market value. High rates of discontinuation lead to a reduction in the total volume of drug consumption, causing sales figures to stagnate despite the increasing global prevalence of mental disorders. Data from the National Community Pharmacists Association in 2025 indicated that up to 50% of patients with chronic conditions failed to take their medications as prescribed. This significant rate of non-compliance, largely driven by tolerability issues, restricts the market's capacity to fully capitalize on the diagnosable patient pool, effectively capping revenue generation and hindering overall industry advancement.

Market Trends

The emergence of antipsychotics utilizing novel non-dopaminergic mechanisms represents a significant market evolution, directly addressing the critical need for effective treatments with enhanced tolerability profiles. Unlike conventional agents that primarily block dopamine D2 receptors, which can lead to metabolic syndrome and motor side effects, this innovative class targets alternative systems, such as muscarinic acetylcholine receptors, to modulate psychotic symptoms. This paradigm shift is attracting substantial investment as manufacturers strive to capture market share from patients who discontinue standard therapies due to adverse events, exemplified by Bristol Myers Squibb's acquisition of Karuna Therapeutics for a total equity value of $14 billion in March 2024, underscoring the industry's massive financial commitment to these first-in-class non-dopaminergic therapies.

Concurrently, the expansion of indications for the adjunctive treatment of Major Depressive Disorder (MDD) is broadening the commercial horizon for third-generation atypical antipsychotics. As monotherapy antidepressants frequently fail to achieve remission in complex cases, clinicians are increasingly prescribing these agents as add-on therapies, effectively unlocking a patient population significantly larger than that of schizophrenia alone. This strategic label expansion enables pharmaceutical companies to maximize the lifecycle value of their assets and sustain growth, even amidst patent pressures in other portfolios. For instance, AbbVie reported in April 2024 that global net revenues for its flagship psychiatric drug Vraylar increased by 23.6% to $694 million, a surge largely driven by its growing adoption in the management of mood disorders, including its use as an adjunctive treatment for MDD.

Key Market Players

  • Eli Lily and Company
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co, Ltd.
  • Pfizer Inc.
  • AbbVie Inc.
  • Dr. Reddy's Laboratories Limited
  • Otsuka Holdings Co., Ltd.
  • Teva Pharmaceutical Industries Ltd

Report Scope

In this report, the Global Antipsychotic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antipsychotic Drugs Market, By Application

  • Schizophrenia
  • Bipolar Disorder
  • Unipolar Disorder
  • Dementia
  • Others

Antipsychotic Drugs Market, By Drug Classification

  • First Generation (Typical)
  • Second Generation (Atypical)

Antipsychotic Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antipsychotic Drugs Market.

Available Customizations:

Global Antipsychotic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antipsychotic Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, Others)
    • 5.2.2. By Drug Classification (First Generation (Typical), Second Generation (Atypical))
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Antipsychotic Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Drug Classification
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antipsychotic Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Drug Classification
    • 6.3.2. Canada Antipsychotic Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Drug Classification
    • 6.3.3. Mexico Antipsychotic Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Drug Classification

7. Europe Antipsychotic Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Drug Classification
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Antipsychotic Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Drug Classification
    • 7.3.2. France Antipsychotic Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Drug Classification
    • 7.3.3. United Kingdom Antipsychotic Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Drug Classification
    • 7.3.4. Italy Antipsychotic Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Drug Classification
    • 7.3.5. Spain Antipsychotic Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Drug Classification

8. Asia Pacific Antipsychotic Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Drug Classification
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Antipsychotic Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Drug Classification
    • 8.3.2. India Antipsychotic Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Drug Classification
    • 8.3.3. Japan Antipsychotic Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Drug Classification
    • 8.3.4. South Korea Antipsychotic Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Drug Classification
    • 8.3.5. Australia Antipsychotic Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Drug Classification

9. Middle East & Africa Antipsychotic Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Drug Classification
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Antipsychotic Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Drug Classification
    • 9.3.2. UAE Antipsychotic Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Drug Classification
    • 9.3.3. South Africa Antipsychotic Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Drug Classification

10. South America Antipsychotic Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Drug Classification
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Antipsychotic Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Drug Classification
    • 10.3.2. Colombia Antipsychotic Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Drug Classification
    • 10.3.3. Argentina Antipsychotic Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Drug Classification

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Antipsychotic Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eli Lily and Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AstraZeneca plc
  • 15.3. GlaxoSmithKline plc
  • 15.4. Johnson & Johnson
  • 15.5. Otsuka Pharmaceutical Co, Ltd.
  • 15.6. Pfizer Inc.
  • 15.7. AbbVie Inc.
  • 15.8. Dr. Reddy's Laboratories Limited
  • 15.9. Otsuka Holdings Co., Ltd.
  • 15.10. Teva Pharmaceutical Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer